HIV-PI

Therapy Area
Protease inhibitor for the treatment of patients with HIV.

 
In phase
Preclinical optimization phase.
Competitive edge
HIV protease inhibitor with highly potent antiviral effect in a cell-based assay has been identified.
Project data
  • Collaboration with Tibotec Pharmaceuticals Ltd. since 30 June 2006
  • Inhibitor with very potent activity against wild-type HIV and resistant virus.
Main products 2006
Kaletra
Abbott
Reyataz Bristol-Myers Sqibb
Crixivan Merck
Viracept Roche
Norvir Abbott

Updated: 28/03/2007

Last Modified: 05/09/2008